Synthetic Studies on the Natural Multidrug Resistance Modulator, Irciniasulfonic Acid B

Chisato Emura, Ryuichi Higuchi, and Tomofumi Miyamoto*

Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582


(Received June 21, 2010; CL-100577; E-mail: miyamoto@phar.kyushu-u.ac.jp)

Synthetic studies on the natural multidrug resistance (MDR) modulator irciniasulfonic acid (ISA)-B utilizing cross metathesis and the Horner–Wadsworth–Emmons olefination is described. The key intermediate, 7-hydroxy-2-nonanone was optically resolved using a cyclopenta[b]furan derivative (ALBO-V).

In our continuing research for bioactive compounds from marine invertebrates, we isolated novel fatty acid analogs, ISA¹ and ISA-B $(1)^2$ from the Japanese marine sponge Ircinia sp. (Figure 1). These compounds reversed multidrug resistance (MDR) against a membrane glycoprotein (termed P-glycoprotein or P-gp) overexpressing cancer cells. In this letter, we report on the synthesis of deacyl ISA-B (2), which is a deacyl derivative of ISA-B. First, the total synthesis of ISA, via a nucleophilic ring-opening reaction with racemic epoxide and hex-1-yne, and a cuprate addition to α,β -unsaturated alkynyl ester was reported by Dobbs's group.³ Because deacyl ISA-B (2) consists of a regioisomeric hydroxy fatty acid, (2Z,8R)-8-hydroxy-3-methyl-2-decenoic acid (18), we opted to synthesize 2 utilizing cross metathesis (CM) reactions⁴ and the Horner-Wadsworth-Emmons (HWE) olefination.5

Treatment of commercially available 1-penten-3-ol (3) with 1 equiv of 5-hexen-2-one (4) and 0.6 mol % of the Hoveyda– Grubbs catalyst 2nd generation 5^6 in refluxing CH₂Cl₂ provided the desired CM product 6 in a yield of 48%. However, the reaction was not carried out efficiently because a self-metathesis of 3 and 4 occurred. It was reported that a two-step CM procedure provided CM products selectively.⁴ According to this method, 1-penten-3-ol (3) was first self-metathesized with catalyst 5 to provide the homodimer 7. Then treatment of compound 7 with 0.5 equiv of 4 and 0.1 mol % of 5 provided the 7-hydroxy-5-nonen-2-one (6)⁷ in a 72% yield (Scheme 1).

The racemic alcohol 8, which was prepared by the catalytic reduction of 6 was optically resolved using (R)-3a-allyl-3,3a,4,5tetrahydro-2H-cyclopenta[b]furan (ALBO-V).8 Treatment of 8 with ALBO-V gave diastereomeric acetal, and this was easily separated into 9 and 10 by silica gel column chromatography $[\Delta R_f \text{ value of } 9/10 \text{ on TLC } 0.05 \text{ (}n\text{-hexane/EtOAc} = 2/1)\text{]. Part}$ of the acetals 9 and 10 were treated with PPTS in MeOH to obtain optically active alcohols 11 and 12, and their specific rotations were $[\alpha]_D = -11.4^\circ$ for 11, and $+11.4^\circ$ for 12, respectively. The absolute configuration at C-7 of 12 was determined to be an S-configuration by the application of a modified Mosher's method,⁹ so that 9 and 11 have Rconfiguration at C-7 in the same way as the natural product. Optically pure acetal 9 reacted with t-butyl diethoxyphosphorylacetate (14) and KOt-Bu to give unsaturated ester 15, which was a mixture of an E/Z (5.5/1) isomer. Because the natural ISA-B has trisubstituted Z-olefin, we attempted Z-selective HE olefination using trifluoroethoxyphosphoryl ester and KN(TMS)₂/18-crown-6,¹⁰ however, the reactivity to ketone




Scheme 1. Cross metathesis reactions using Hoveyda–Grubbs catalyst 2nd generation.

was poor, so that 2Z,8R (15a) and 2E,8R (15b) olefin was separated by silica gel column chromatography. The structures of 15a and 15b were confirmed by the characteristic allylic methyl and methylene proton signals in ¹H NMR [15a: $\delta_{\rm H}$ 1.81 (3H, d, J = 1.3 Hz), 2.57 (2H, m)]. Before the deprotection of the *t*-butyl group of 15a, cyclopenta[*b*]furanoacetal was replaced with the acetyl group to avoid hydroxy elimination. Compound 15a was treated with PPTS to give hydroxy derivative 16. Next, the hydroxy group was protected with Ac₂O/pyridine to give acetyl derivative 17. The *t*-butyl group in 17 was removed using TFA, and then the acetyl group was removed using NaOMe to afford (2*Z*,8*R*)-8-hydroxy-3-methyl-2-decenoic acid (18),¹¹ successively.

Finally, direct condensation of hydroxy fatty acid **18** and taurine using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM)¹² gave deacyl ISA-B (**2**) (Scheme 2). The spectroscopic data of **2** was in full agreement with those of the deacyl derivative of natural ISA-B.¹³

In conclusion, we have developed a synthesis of optically pure deacyl ISA-B using a CM reaction followed by HWE olefination via chiral resolution with ALBO-V. This method is applicable for obtaining stereoisomer of deacyl ISA-B. The reversing MDR activities of the ISA-B analogs will be reported elsewhere.



Scheme 2. Reagents and conditions: (i) H₂, Rh–Al₂O₃, EtOH, 0 °C, 3 h, 72%; (ii) ALBO-V, PPTS, CH₂Cl₂, rt, 1.5 h, **9**: 45%, **10**: 50%; (iii) PPTS, MeOH, rt, **11**: 68%, **12**: 85%, **16**: 45%; (iv) (*R*)- or (*S*)-MTPACl, pyridine, rt, 3.5 h; (v) (EtO)₂P(O)CH₂-COO*t*-Bu (**14**), KO*t*-Bu, THF, 0 °C–rt, 12 h, **15a**: 11%, **15b**: 60%; (vi) Ac₂O, pyridine, rt; (vii) TFA, CH₂Cl₂, rt; (viii) 0.1 M NaOMe, MeOH, rt, 84% (yield of vi–viii); (ix) taurine, DMT-MM, *N*-methylmorpholine, acetone/H₂O, rt, 12 h, 46%.

The authors would like to thank ZEON Corporation for donating ALBO-V. This work was supported by a Research Fellowships of the Japan Society for the Promotion of Science (JSPS) for Young Scientists 19-9814, and by a Grant-in-Aid for Scientific Research on Priority Areas No. 40182050 from The Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.

References and Notes

 A. Kawakami, T. Miyamoto, R. Higuchi, T. Uchiumi, M. Kuwano, R. W. M. Van Soest, *Tetrahedron Lett.* 2001, 42, 3335.

- 2 C. Emura, R. Higuchi, T. Miyamoto, *Tetrahedron* **2006**, *62*, 5682.
- 3 A. P. Dobbs, A. Venturelli, L. A. Butler, R. J. Parker, *Synlett* 2005, 652.
- 4 H. E. Blackwell, D. J. O'Leary, A. K. Chatterjee, R. A. Washenfelder, D. A. Bussmann, R. H. Grubbs, *J. Am. Chem. Soc.* 2000, 122, 58.
- 5 W. S. Wadsworth, W. D. Emmons, *J. Am. Chem. Soc.* **1961**, *83*, 1733.
- 6 S. B. Garber, J. S. Kingsbury, B. L. Gray, A. H. Hoveyda, J. Am. Chem. Soc. 2000, 122, 8168.
- 7 Compound 6: ¹H NMR (400 MHz, CDCl₃): δ 0.88 (3H, t, J = 7.5 Hz, H-9), 1.51 (2H, m), 2.12 (3H, s, H-1), 2.30 (2H, m, H-4), 2.51 (2H, t, J = 7.3 Hz, H-3), 3.95 (1H, m, H-7), 5.46 (1H, dd, J = 6.8, 15.4 Hz, H-6), 5.62 (1H, dt, J = 15.4, 6.5 Hz, H-5).
- 8 a) H. Nemoto, *Tetrahedron Lett.* 1994, 35, 7785. b) H. Nemoto, W. Zhong, T. Kawamura, M. Kamiya, Y. Nakano, K. Sakamoto, *Synlett* 2007, 2343.
- 9 I. Ohtani, T. Kusumi, Y. Kashman, H. Kakisawa, J. Am. Chem. Soc. 1991, 113, 4092; (R)-MTPA ester (13a): ¹H NMR (400 MHz, CDCl₃): δ 0.895 (3H, t, J = 7.3 Hz, H-9), 1.151 (2H, m, H-5), 2.087 (3H, s, H-1), 2.309 (2H, t, J = 7.3 Hz, H-3), 5.002 (1H, m, H-7); (S)-MTPA ester (13b): ¹H NMR (400 MHz, CDCl₃): δ 0.789 (3H, t, J = 7.3 Hz, H-9), 1.286 (2H, m, H-5), 2.101 (3H, s, H-1), 2.380 (2H, t, J = 7.3 Hz, H-3), 5.005 (1H, m, H-7).
- 10 W. C. Still, C. Gennari, Tetrahedron Lett. 1983, 24, 4405.
- 11 Compound **18**: ¹H NMR (400 MHz, CDCl₃): δ 0.92 (3H, t, J = 7.5 Hz, H-10), 1.33–1.53 (8H, methylenes), 1.89 (3H, d, J = 1.3 Hz, H-11), 2.62 (2H, t, J = 6.4 Hz, H-4), 3.51 (1H, m, H-8), 5.66 (1H, s, H-2).
- 12 M. Kunishima, C. Kawachi, K. Hioki, K. Terao, S. Tani, *Tetrahedron* 2001, 57, 1551.
- 13 Synthetic deacyl ISA-B (2): $[\alpha]_D + 8.0^\circ$ (*c* 0.24, MeOH), deacyl derivative of natural ISA-B: $[\alpha]_D + 9.0^\circ$ (*c* 1.0, MeOH), negative HRFABMS *m/z*: 306.1308 [M - H]⁻ calcd for C₁₃H₂₄O₅NS Δ mmu = -6.7, ¹H NMR (600 MHz, CD₃OD): δ 0.92 (3H, t, *J* = 7.3 Hz, H-10), 1.28-1.48 (8H, methylenes), 1.83 (3H, d, *J* = 1.0 Hz, H-11), 2.60 (2H, t, *J* = 6.8 Hz, H-4), 2.96 (2H, t, *J* = 6.8 Hz, H-2'), 3.43 (1H, m, H-8), 3.60 (2H, t, *J* = 6.8 Hz, H-1'), 5.64 (1H, s, H-2).